@article {HacohenS51.008作者={雅艾尔Hacohen Wong团队和基督教拥有莱希和Maciej Jurynczyk Sukhvir赖特和Bahadir Konuskan和安妮丽莎Poulat海琳Maurey和伊万杰琳沃斯默谢丽尔海明威和伊娃玛丽亚海和玛丽亚·雷特和奥尔加Ciccarelli Banu Anlar和Rogier Hintzen罗曼Marignier和杰奎琳宫和马提亚鲍曼和凯文Rostesy Rinze f . Neuteboom和库玛Deiva明Lim}, title ={疾病和治疗反应在儿童复发髓少突细胞糖蛋白抗体(MOG-Ab)相关疾病(S51.008)},体积={90}={15}补充数量,elocation-id = {S51.008} ={2018},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:描述临床表型,治疗反应和复发MOG-Ab-associated患儿疾病的结果。首页背景:MOG-Ab一直确认的脱髓鞘疾病的成人和儿童。当前的治疗策略主要是center-specific和没有正式evaluatedDesign /治疗方法:前瞻性收集人口、临床和放射学数据来自8个国家的欧盟儿科脱髓鞘疾病财团。患者治疗根据当地协议。年复发率(ARR)和扩展残疾状态量表(eds)评分和治疗疾病修饰药物(诊断)计算。结果:102名儿童被识别;他们最初的诊断视神经节neuromyelitis谱系障碍(43.1 \ %),急性播散性脑脊髓炎其次是视神经炎(19.6 \ %)、多相播散性脑脊髓炎(19.6 \ %),复发性视神经炎(17.6 \ %)。总共有464脱髓鞘事件队列中被报道。没有差异,病人{\ textquoteright}年代人口和脱髓鞘表现型之间发病和治疗病人治疗,但是治疗病人有更多的复发(p = 0.0094)和eds (p \ < 0.0001)高于未经处理的。诊断有52(51 \ %)孩子们:28(53.8 \ %)患者治疗DMD, 17(32.7 \ %)和两个,7(13.5 \ %)和三个或更多的连续监测诊断。在所有治疗复发的患者共有127复发治疗报告队列。任何更改在加勒比海盗和eds观察pre -和β干扰素post-initiation glatiramer醋酸(n = 11)。加勒比海盗与咪唑硫嘌呤从1.84减少到1.0 (n = 20, p = 0.0004);1.79到0.52,霉酚酸酯(n = 15, p = 0.0028); 2.12 to 0.67 with Rituximab(n=9, p=0.0008), although the EDSS remained unchanged. An improvement in both ARR (2.16 to 0.51, p\<0.0001) and EDSS (2.2 to 1.2, p=0.013) was observed in patients treated with regular intravenous immunoglobulins (n=12).Conclusions: DMDs commonly used to treat MS patients were not associated with clinical improvement in children with MOG-Ab-associated disease, whilst azathioprine, mycophenolate mofetil, Rituximab, and particularly IVIG, were associated with a reduction in relapse frequency.Disclosure: Dr. Hacohen has nothing to disclose. Dr. Yuyi has nothing to disclose. Dr. Lechner has nothing to disclose. Dr. Jurynczyk has nothing to disclose. Dr. Wright has nothing to disclose. Dr. Konuskan has nothing to disclose. Dr. Poulat has nothing to disclose. Dr. Maurey has nothing to disclose. Dr. Wassmer has nothing to disclose. Dr. Hemingway has nothing to disclose. Dr. Hennes has nothing to disclose. Dr. Leite has nothing to disclose. Dr. Ciccarelli has nothing to disclose. Dr. Anlar has nothing to disclose. Dr. Hintzen has nothing to disclose. Dr. Marignier has nothing to disclose. Dr. Palace has nothing to disclose. Dr. Baumann has nothing to disclose. Dr. Rostasy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with served as a consultant for PARADIGMS study. Dr. Neuteboom has nothing to disclose. Dr. Deiva has nothing to disclose. Dr. Lim has nothing to disclose.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/90/15_Supplement/S51.008}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }